Effect of repeated administration of paroxetine and electroconvulsive shock on the proliferative response of lymphocytes and the synthesis of nitric oxide by macrophages in rats

Journal of ECT

Volumn 21, Issue 2, 2005, Pages 111-117

  Roman, Adam ^a   Nalepa, Irena ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

ECS; Macrophages; Nitric oxide (NO); Paroxetine; Proliferative response of lymphocytes

Indexed keywords

CONCANAVALIN A; MITOGENIC AGENT; NITRIC OXIDE; PAROXETINE; THYMIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DEPRESSION; ELECTROCONVULSIVE THERAPY; IMMUNOMODULATION; LYMPHOCYTE; MALE; NONHUMAN; PERITONEUM MACROPHAGE; RAT; SPLEEN CELL; T LYMPHOCYTE; THYMOCYTE;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BODY WEIGHT; CELL DIVISION; DRUG ADMINISTRATION SCHEDULE; ELECTROSHOCK; LIPOPOLYSACCHARIDES; LYMPHOCYTES; MACROPHAGES, PERITONEAL; MALE; NITRIC OXIDE; ORGAN SIZE; PAROXETINE; RATS; RATS, WISTAR; SPLEEN;

EID: 20444390502     PISSN: 10950680     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yct.0000167462.33586.6d     Document Type: Article

References (50)

1. Nalepa I, Sulser F. New hypotheses to guide future antidepressant drug development. In: Preskorn SH, Feighner JP, Staga CY, et al., eds. Antidepressants: Past, Present and Future. Handbook of Experimental Pharmacology. Berlin: Springer-Verlag; 2004:519-563.
2. Leonard BE. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:767-780.
3. Elenkov IJ, Wilder RL, Chrousos GP, et al. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52:595-638.
4. Mössner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun. 1998;12:249-271.
5. Kronfol Z. Immune dysregulation in major depression: a critical review of existing evidence. Int J Neuropsychopharmacol. 2002;5:333-343.
6. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15:199-226.
7. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol. 2002;5:375-388.
8. Leonard BE, Song C. Changes in the immune system in rodent model of depression. Int J Neuropsychopharmacol. 2002;5:345-356.
9. Frank MG, Hendricks SE, Johnson DR, et al. Antidepressants augment natural killer cell activity: in vivo and in vitro. Neuropsychobiology. 1999;39:18-24.
10. Xia Z, DePierre JW, Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology. 1996;34:27-37.
11. Kubera M, Lin AH, Kenis G, et al. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol. 2001;21:199-206.
12. Kubera M, Maes M. Serotonin-immune interactions in major depression. In: Patterson P, Kordon C, Christen Y, eds. Neuro-immune Interactions in Neurologic and Psychiatric Disorders. Berlin: Springer-Verlag; 2000:79-87.
13. Crowson AN, Magro CM. Antidepressant therapy. A possible cause of atypical cutaneous lymphoid hyperplasia. Arch Dermatol. 1995;131:925-929.
14. Reed SM, Glick JW. Fluoxetine and reactivation of the herpes simplex virus. Am J Psychiatry. 1991;148:949-950.
15. Kubera M, Simbirtsev A, Mathison R, et al. Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res. 2000;96:255-266.
16. Pellegrino TC, Bayer BM. Modulation of immune cell function following fluoxetine administration in rats. Pharmacol Biochem Behav. 1998;59:151-157.
17. Roman A, Vetulani J, Nalepa I. Effect of combined treatment with paroxetine and transcranial magnetic stimulation (TMS) on the mitogen-induced proliferative response of rat lymphocytes. Pol J Pharmacol. 2002;54:633-639.
18. Jaju BP, Srivastava AK, Agarwal AK, et al. Effect of electroconvulsions on leucocyte counts. Indian J Exp Biol. 1990;28:329-332.
19. Fischler B, Bocken R, Schneider l, et al. Immune changes induced by electroconvulsive therapy (ECT). Ann N Y Acad Sci. 1992;650:326-330.
20. Vlajkovic S, Jankovic BD. Experimental epilepsy: electrically and chemically induced convulsions modulate experimental allergic encephalomyelitis and other immune inflammatory reactions in the rat. Int J Neurosci. 1990;54:165-172.
21. Nalepa I, Chalecka-Franaszek E, Vetulani J. The antagonistic effect of separate and consecutive chronic treatment with imipramine and ECS on the regulation of alpha1-adrenoceptor activity by protein kinase C. Pol J Pharmacol. 1993;45:521-532.
22. Nalepa I, Vetulani J. Modulation of electroconvulsive treatment induced beta-adrenergic down-regulation by previous chronic imipramine administration: The involvement of protein kinase C. Pol J Pharmacol. 1996;48:489-494.
23. Nalepa I, Chalecka-Franaszek E, Vetulani J. Modulation by mianserin pretreatment of the chronic electroconvulsive shock effects on the adrenergic system in the cerebral cortex of the rat. Human Psychopharmacol Clin Exp. 1996;11:273-282.
24. Vetulani J, Nalepa I. The effect of chronic administration of amitriptyline on the effects of subsequent electroconvulsive treatment on responsiveness of alpha1- and beta-adrenoceptors in the rat cortical slices. J Neural Transm. 1996;103:363-376.
25. Janossy G, Shorat M, Greaves MF, et al. Lymphocyte activation. IV. The ultrasrtuctural pattern of the response of mouse T and B cells to mitogenic stimulation in vitro. Immunology. 1972;24:211-227.
26. Mills CD, Kincaid K, Alt JM, et al. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166-6173.
27. Mills CD. Molecular basis of "suppressor" macrophages. Arginine metabolism via the nitric oxide synthetase pathway. J Immunol. 1991;146:2719-2723.
28. Albina JE, Abate JA, Henry WL Jr. Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation. Role of IFN-gamma in the induction of the nitric oxide-synthesizing pathway. J Immunol. 1991;147:144-148.
29. Marcinkiewicz J, Pater M, Grabowska A. An improved experimental model for the study of in vitro release of nitric oxide by murine peritoneal macrophages. Arch Immunol Ther Exp (Warsz). 1994;42:95-99.
30. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected in the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol. 1998;160:5347-5354.
31. Smith RS. The macrophage theory of depression. Med Hypotheses. 1991;35:298-306.
32. Pryjma J, Zembala M, Pituch-Noworolska A, et al. Monocyte-T-cell interactions in pokeweed mitogen-activated cultures. Immunology. 1990;71:397-403.
33. Radojcic T, Baird S, Darko D, et al. Changes in beta-adrenergic receptor distribution on immunocytes during differentiation: an analysis of T cells and macrophages. J Neurosci Res. 1991;30:328-335.
34. Straub RH, Westermann J, Scholmerich J, et al. Dialogue between the CNS and the immune system in lymphoid organs. Immunol Today. 1998;19:409-413.
35. Felten DL, Felten SY, Bellinger DL, et al. Noradrenergic sympathetic neural interactions with the immune system: structure and function. Immunol Rev. 1987;100:225-260.
36. Panina-Bordignon P, Mazzeo D, Lucia PD, et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest. 1997;100:1513-1519.
37. Chou RC, Stinson MW, Noble BK, et al. Beta-adrenergic receptor regulation of macrophage-derived tumor necrosis factor-alpha production from rats with experimental arthritis. J Neuroimmunol. 1996;67:7-16.
38. Sigola LB, Zinyama RB. Adrenaline inhibits macrophage nitric oxide production through beta1 and beta2 adrenergic receptors. Immunology. 2000;100:359-363.
39. Thomas DN, Nutt DJ, Holman RB. Effects of acute and chronic electroconvulsive shock on noradrenaline release in the rat hippocampus and frontal cortex. Br J Pharmacol. 1992;106:430-434.
40. Thiagarajan AB, Gleiter CH, Mefford IN, et al. Effect of single and repeated electroconvulsive shock on the hypothalamic-pituitary-adrenal axis and plasma catecholamines in rats. Psychopharmacology (Berl). 1989;97:548-552.
41. Faraj BA, Olkowski ZL, Jackson RT. Expression of high-affinity serotonin transporter in human lymphocytes. Int J Immunopharmacol. 1994;16:561-567.
42. Jackson JC, Walker RF, Brooks WH, et al. Specific uptake of serotonin by murine macrophages. Life Sci. 1988;42:1641-1650.
43. Kut JL, Young MR, Crayton JW, et al. Regulation of murine T-lymphocyte function by spleen cell-derived and exogenous serotonin. Immunopharmacol Immunotoxicol. 1992;14:783-796.
44. Young MR, Kut JL, Coogan MP, et al. Stimulation of splenic T-lymphocyte function by endogenous serotonin and by low-dose exogenous serotonin. Immunology. 1993;80:395-400.
45. Pellegrino TC, Bayer BM. Specific serotonin reuptake inhibitor-induced decreases in lymphocyte activity require endogenous serotonin release. Neuroimmunomodulation. 2000;8:179-187.
46. Henderson DC, Edwards RG, Weston BJ, et al. Immunological studies on paroxetine, a novel anti-depressant drug. Int J Immunopharmacol. 1988;10:361-367.
47. Konkle AT, Sreter KB, Baker SL, et al. Chronic paroxetine infusion influences macronutrient selection in male Sprague-Dawley rats. Pharmacol Biochem Behav. 2003;74:883-890.
48. Jackson HC, Needham AM, Hutchins LJ, et al. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol. 1997;121:1758-1762.
49. Gehlert DR, Dreshfield L, Tinsley F, et al. The selective norepinephrine reuptake inhibitor, LY368975, reduces food consumption in animal models of feeding. J Pharmacol Exp Ther. 1998;287:2122-127.
50. Ishihara K, Sasa M. Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Jpn J Pharmacol. 1999;80:185-189.